MA37616A1 - Formulation liquide d'anticorps anti-baffr pour une utilisation dans le traitement de maladies auto-immunes et du neoplasme cellulaire. - Google Patents

Formulation liquide d'anticorps anti-baffr pour une utilisation dans le traitement de maladies auto-immunes et du neoplasme cellulaire.

Info

Publication number
MA37616A1
MA37616A1 MA37616A MA37616A MA37616A1 MA 37616 A1 MA37616 A1 MA 37616A1 MA 37616 A MA37616 A MA 37616A MA 37616 A MA37616 A MA 37616A MA 37616 A1 MA37616 A1 MA 37616A1
Authority
MA
Morocco
Prior art keywords
treatment
autoimmune diseases
antibody formulation
liquid anti
baffr antibody
Prior art date
Application number
MA37616A
Other languages
English (en)
Inventor
Marta Cosenza
Christoph Stark
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48914378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37616(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA37616A1 publication Critical patent/MA37616A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des anticorps anti-baffr formulés en tant que formulation liquide comprenant une concentration élevée d'un ingrédient actif d'anticorps à administrer à un patient sans niveaux élevés d'agrégation d'anticorps. La composition pharmaceutique aqueuse peut comprendre un ou plusieurs sucre(s), un agent tampon, un tensioactif, et/ou un acide aminé libre.
MA37616A 2012-06-12 2013-06-10 Formulation liquide d'anticorps anti-baffr pour une utilisation dans le traitement de maladies auto-immunes et du neoplasme cellulaire. MA37616A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261658472P 2012-06-12 2012-06-12
PCT/IB2013/054777 WO2013186700A1 (fr) 2012-06-12 2013-06-11 Formulation d'anticorps

Publications (1)

Publication Number Publication Date
MA37616A1 true MA37616A1 (fr) 2017-08-31

Family

ID=48914378

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37616A MA37616A1 (fr) 2012-06-12 2013-06-10 Formulation liquide d'anticorps anti-baffr pour une utilisation dans le traitement de maladies auto-immunes et du neoplasme cellulaire.

Country Status (36)

Country Link
US (4) US9216219B2 (fr)
EP (2) EP3593814A1 (fr)
JP (1) JP6265978B2 (fr)
KR (1) KR102124820B1 (fr)
CN (1) CN104363920B (fr)
AR (1) AR091413A1 (fr)
AU (1) AU2013276112B2 (fr)
BR (1) BR112014030820B1 (fr)
CA (1) CA2875386C (fr)
CL (1) CL2014003370A1 (fr)
CO (1) CO7151487A2 (fr)
CY (1) CY1122181T1 (fr)
DK (1) DK2858671T3 (fr)
EA (1) EA033373B1 (fr)
EC (1) ECSP15017314A (fr)
ES (1) ES2751659T3 (fr)
GT (1) GT201400285A (fr)
HK (1) HK1203146A1 (fr)
HR (1) HRP20191827T1 (fr)
HU (1) HUE045523T2 (fr)
IL (1) IL235966B (fr)
LT (1) LT2858671T (fr)
MA (1) MA37616A1 (fr)
MX (1) MX363380B (fr)
MY (1) MY179818A (fr)
NZ (1) NZ630885A (fr)
PE (1) PE20150200A1 (fr)
PH (1) PH12014502778A1 (fr)
PL (1) PL2858671T3 (fr)
PT (1) PT2858671T (fr)
SG (1) SG11201408174UA (fr)
SI (1) SI2858671T1 (fr)
TN (1) TN2014000488A1 (fr)
TW (1) TWI653983B (fr)
WO (1) WO2013186700A1 (fr)
ZA (1) ZA201408547B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3459564T (lt) 2010-01-06 2022-03-10 Takeda Pharmaceutical Company Limited Plazmos kalikreiną surišantys baltymai
US9458240B2 (en) * 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
TW201922795A (zh) 2012-09-10 2019-06-16 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
KR20150132473A (ko) 2013-03-15 2015-11-25 다이액스 코포레이션 항-혈장 칼리크레인 항체
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CN104730237A (zh) * 2013-12-23 2015-06-24 国家纳米科学中心 试纸及其应用以及检测甲胎蛋白抗原、乙肝表面抗原或HIV的gp41抗体的方法
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
EP3116911B8 (fr) 2014-03-12 2019-10-23 Prothena Biosciences Limited Anticorps anti-mcam et procédés d'utilisation associés
EP3122782A4 (fr) 2014-03-27 2017-09-13 Dyax Corp. Compositions et procédés pour le traitement de l'oedème maculaire diabétique
KR101597037B1 (ko) 2014-06-26 2016-02-24 엘지디스플레이 주식회사 구동소자의 전기적 특성 편차를 보상할 수 있는 유기발광 표시장치
TWI705827B (zh) 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3286226A4 (fr) * 2015-03-30 2018-12-05 Dyax Corp. Inhibiteurs de la kallicréine plasmatique et utilisations desdits inhibiteurs pour prévenir un accès d'angio-oedème héréditaire
CA2998716A1 (fr) * 2015-09-16 2017-03-23 Prothena Biosciences Limited Utilisation d'anticorps anti-mcam pour le traitement ou la prophylaxie de l'arterite a cellules geantes, la pseudo-polyarthrite rhizomelique ou l'arterite de takayasu
RS61029B1 (sr) * 2015-12-07 2020-12-31 Merck Patent Gmbh Vodena formulacija koja sadrži avelumab antitelo na pd-1
AU2016366557B2 (en) 2015-12-11 2024-01-25 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
WO2017104778A1 (fr) * 2015-12-18 2017-06-22 アステラス製薬株式会社 Composition pharmaceutique contenant un anticorps anti-récepteur de la tslp humaine
AU2017286375B2 (en) * 2016-06-16 2019-04-18 Janssen Vaccines & Prevention B.V. HIV vaccine formulation
AU2017345454A1 (en) 2016-10-19 2019-05-30 Invenra Inc. Antibody constructs
MX2019007019A (es) 2016-12-22 2019-08-16 Univ Degli Studi Magna Graecia Catanzaro Anticuerpo monoclonal dirigido a un epitope de cd43 sialoglicosilado especifico asociado al cancer.
EP3589318A1 (fr) * 2017-03-01 2020-01-08 MedImmune Limited Formulations d'anticorps monoclonaux
SG11201908091QA (en) * 2017-03-06 2019-10-30 Merck Patent Gmbh Aqueous anti-pd-l1 antibody formulation
US11639391B2 (en) * 2017-04-18 2023-05-02 Dr. Reddy's Laboratories Limited Stable liquid pharmaceutical composition
BR112020001703B1 (pt) * 2017-07-27 2024-01-02 Alexion Pharmaceuticals, Inc Solução aquosa estável compreendendo um anticorpo anti-c5, método para produção desta solução, uso da mesma para tratar uma condição associada ao complemento e kit terapêutico compreendendo a mesma
IL272773B2 (en) * 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
AU2018375356A1 (en) * 2017-11-29 2020-05-14 Neotope Neuroscience Limited Lyophilized formulation of a monoclonal antibody against transthyretin
CN113227127A (zh) 2018-06-05 2021-08-06 伦敦大学国王学院 向胃肠系统递送酬载的btnl3/8导引构建体
MX2021007393A (es) * 2018-12-18 2021-09-23 Novartis Ag Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf.
BR112021015034A2 (pt) 2019-02-18 2021-10-05 Eli Lilly And Company Formulação de anticorpo terapêutico
WO2020173431A2 (fr) * 2019-02-26 2020-09-03 信达生物制药(苏州)有限公司 Préparations contenant un anticorps anti-cd47, leur procédé de préparation et utilisation associée
AU2020377872A1 (en) 2019-11-06 2022-05-26 Novartis Ag Treatment for Sjogren's Syndrome
CN113116812A (zh) * 2019-12-30 2021-07-16 百奥泰生物制药股份有限公司 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用
CA3168600A1 (fr) * 2020-01-21 2021-07-29 Innovent Biologics (Suzhou) Co., Ltd. Preparations d'anticorps monoclonaux anti-tigit recombinants entierement humains, leur procede de preparation et leur utilisation
JP2023536596A (ja) 2020-08-04 2023-08-28 ノバルティス アーゲー Ｂ細胞悪性腫瘍の治療
CN115073598B (zh) * 2021-03-15 2024-02-20 盛禾(中国)生物制药有限公司 一种抗baffr抗体及其应用
EP4334351A1 (fr) 2021-05-04 2024-03-13 Novartis AG Traitement du lupus érythémateux disséminé à l'aide d'anticorps anti-baffr
TW202302147A (zh) 2021-05-04 2023-01-16 瑞士商諾華公司 使用抗baffr抗體治療狼瘡腎炎
JP2024537772A (ja) * 2021-09-29 2024-10-16 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｂａｆｆ－ｒを標的化する抗体及びその使用
CN118681009A (zh) * 2023-03-21 2024-09-24 百奥泰生物制药股份有限公司 一种复方制剂及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
EP2275541B1 (fr) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Procédé de contrôle de l'activité d'une molécule fonctionnelle immunologiquement
EP1192243A4 (fr) 1999-06-23 2003-05-28 Univ Oregon Health & Science Procede destine a promouvoir l'hematopoiese
WO2002000879A2 (fr) 2000-06-28 2002-01-03 Glycofi, Inc. Procede de production de glycoproteines modifiees
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
CA2466034C (fr) 2001-11-08 2012-12-18 Protein Design Labs, Inc. Formulations pharmaceutiques aqueuses stables d'anticoprs daclizumab
EP1946776B1 (fr) 2002-02-27 2017-01-18 Immunex Corporation Composition tnfr-fc stabilisée comportant une arginine
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005323025A1 (en) * 2004-12-31 2006-07-13 Biogen Idec Ma Inc. Polypeptides that bind BR3 and uses thereof
JP5767109B2 (ja) * 2008-07-17 2015-08-19 ノバルティス アーゲー 治療抗体を用いる組成物及び方法
CA2780554C (fr) * 2009-11-17 2017-08-15 Ipsen Pharma S.A.S. Preparation pour combinaison d'hormones de croissance humaine (hgh) et de rhigf-1
US9458240B2 (en) * 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
WO2013083497A1 (fr) 2011-12-06 2013-06-13 F. Hoffmann-La Roche Ag Formulation d'anticorps
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation

Also Published As

Publication number Publication date
MX363380B (es) 2019-03-21
US20130344088A1 (en) 2013-12-26
SI2858671T1 (sl) 2019-11-29
ES2751659T3 (es) 2020-04-01
WO2013186700A1 (fr) 2013-12-19
EP2858671B1 (fr) 2019-07-24
HRP20191827T1 (hr) 2019-12-27
JP2015521593A (ja) 2015-07-30
HK1203146A1 (en) 2015-10-23
IL235966A0 (en) 2015-01-29
JP6265978B2 (ja) 2018-01-24
LT2858671T (lt) 2019-10-25
PH12014502778B1 (en) 2015-02-02
KR20150029683A (ko) 2015-03-18
BR112014030820A2 (pt) 2017-07-25
TN2014000488A1 (en) 2016-03-30
MY179818A (en) 2020-11-16
DK2858671T3 (da) 2019-10-21
PH12014502778A1 (en) 2015-02-02
EP3593814A1 (fr) 2020-01-15
EA033373B1 (ru) 2019-10-31
TW201402144A (zh) 2014-01-16
TWI653983B (zh) 2019-03-21
CN104363920B (zh) 2018-05-04
NZ630885A (en) 2016-01-29
EP2858671A1 (fr) 2015-04-15
US20160145341A1 (en) 2016-05-26
CA2875386C (fr) 2022-09-13
HUE045523T2 (hu) 2020-01-28
US9751951B2 (en) 2017-09-05
PE20150200A1 (es) 2015-02-08
IL235966B (en) 2020-05-31
MX2014015262A (es) 2015-06-23
CO7151487A2 (es) 2014-12-29
CL2014003370A1 (es) 2015-02-06
KR102124820B1 (ko) 2020-06-22
US20180051092A1 (en) 2018-02-22
BR112014030820B1 (pt) 2023-02-07
GT201400285A (es) 2015-10-15
ECSP15017314A (es) 2018-06-30
US9216219B2 (en) 2015-12-22
US20180251564A1 (en) 2018-09-06
CY1122181T1 (el) 2020-11-25
ZA201408547B (en) 2015-12-23
AR091413A1 (es) 2015-02-04
PL2858671T3 (pl) 2020-01-31
US10689451B2 (en) 2020-06-23
CN104363920A (zh) 2015-02-18
AU2013276112A1 (en) 2014-12-18
AU2013276112B2 (en) 2015-07-09
PT2858671T (pt) 2019-10-28
EA201492292A1 (ru) 2015-04-30
SG11201408174UA (en) 2015-01-29
CA2875386A1 (fr) 2013-12-19

Similar Documents

Publication Publication Date Title
MA37616A1 (fr) Formulation liquide d'anticorps anti-baffr pour une utilisation dans le traitement de maladies auto-immunes et du neoplasme cellulaire.
BR112014027116A2 (pt) formulação de anticorpo
EA201790989A1 (ru) Стабильный препарат раствора белка, содержащего анти-vegf антитело в высокой концентрации
Malcolm et al. Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques
Forbes et al. Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc
Ofotokun et al. HIV and bone metabolism
Hartjen et al. Assessment of the range of the HIV-1 infectivity enhancing effect of individual human semen specimen and the range of inhibition by EGCG
PH12015502441B1 (en) Anti-il-4/anti-il-13 bispecific antibody formulations
Murphy et al. Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir
WO2012076670A3 (fr) Formulation d'anticorps
MA48462B1 (fr) Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation
ATE506071T1 (de) Formulierung für proteinarzneimittel ohne zusatz von humanem serumalbumin (hsa)
PE20100123A1 (es) Una formulacion solida de dosificacion farmaceutica
Akhigbe et al. Viral infections and male infertility: a comprehensive review of the role of oxidative stress
EA200800360A1 (ru) Формуляции с высоким содержанием лекарства и дозированные формы
Dezzutti et al. Pharmacodynamic activity of dapivirine and maraviroc single entity and combination topical gels for HIV-1 prevention
AR091530A1 (es) Formulacion farmaceutica liquida de un anticuerpo y acetato
Li et al. Efficacy, stability, and biosafety of sifuvirtide gel as a microbicide candidate against HIV-1
McBride et al. Pharmacokinetics of the protein microbicide 5P12-RANTES in sheep following single-dose vaginal gel administration
CR20210318A (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf
Haskelberg et al. Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapy
Conradie et al. A direct comparison of the effects of the antiretroviral drugs stavudine, tenofovir and the combination lopinavir/ritonavir on bone metabolism in a rat model
Küng et al. In vitro effect of octenidine dihydrochloride against Trichomonas vaginalis
Rubio et al. Complicaciones microvasculares: nefropatía diabética
Budge et al. Inhibition of respiratory syncytial virus by RhoA-derived peptides: implications for the development of improved antiviral agents targeting heparin-binding viruses